Our CEO participated in the Alzheimer’s Drug Discovery Foundation Investigators Day to explain ADmit’s technology based on novel biomarkers in blood for the prognosis of Alzheimer’s disease. In addition, two posters were presented during the AD/PD 2024 congress in Lisbon (Poster Shift1 0299: Analytical validation of blood mitochondrial methylcytosines for the prognosis of AD dementia progression at MCI stage, and Poster Shift1 0487: Diagnosis of Dementia with Lewy Bodies based on a NGS analysis of blood mitochondrial methylcytosines: a machine learning approach) by Marta Blanch, our product development manager.
